Zosano Pharma, Inc. to Provide Pipeline Updates at the 2009 AAPS Annual Meeting
FREMONT, Calif.--(BUSINESS WIRE)--Nov 2, 2009 - Zosano Pharma, Inc., a privately held pharmaceutical company developing products using a novel transdermal delivery technology, today announced that the company will present two posters at the 2009 Annual Meeting of the American Association of Pharmaceutical Sciences (AAPS) on November 10 in Los Angeles, Calif. at the Los Angeles Convention Center.
One poster titled "Demonstrating 2-year Ambient Storage Shelf Life for Parathyroid Hormone PTH (1-34) Coated on a Novel Transdermal Microprojection Delivery System" highlights the formulation and packaging of the company's novel PTH-coated transdermal microprojection system that was tested in the recent Phase 2 clinical study of its lead product, the ZP-PTH rapid delivery patch. The product is being developed as an alternative to daily injections for the treatment of osteoporosis. ZP-PTH delivers PTH 1-34, teriparatide (PTH), a compound proven to stimulate formation of new bone and reduce the risk of fractures.
A second poster titled "Erythropoietin (EPO) Coated Microprojection Transdermal System: Preclinical Formulation, Stability and Delivery" demonstrates coating and stability of erythropoietin (EPO) on Zosano's transdermal microprojection system. Zosano is developing a transdermal delivery formulation of EPO as a patient friendly, potential alternative to currently available injectable formulations.
Both posters will be presented on November 10th (8:00 AM - 12:00PM/ Poster numbers PTH T-2230 and EPO T-2245)
About Zosano Pharma, Inc.
Zosano Pharma, Inc. is a privately held pharmaceutical company developing products based on its novel transdermal delivery technology for a broad range of therapeutic indications. Its lead clinical program, the ZP-PTH rapid delivery patch for the treatment of osteoporosis, is being developed as an alternative to daily injections. Zosano's transdermal delivery technology is capable of delivering peptides, proteins, small molecules and vaccines by permeating the skin's outer layer and ensuring significant therapeutic effect. This proven proprietary technology offers several key benefits, including efficacy and safety comparable to approved injectables, needle-free delivery, a self-administered patch, rapid onset of action and room temperature storage. Zosano's transdermal delivery technology has been clinically tested in over 400 patients with four different peptides and a vaccine. Zosano aims to develop products both independently and through strategic licensing and co-development arrangements. Founded in 2006 as an ALZA Corporation spin-out led by Nomura Phase4 Ventures, Zosano is funded by New Enterprise Associates, Nomura Phase4 Ventures, HBM BioVentures and ProQuest Investments. For more information, please visit www.zosanopharma.com.
Contact: Zosano Pharma, Inc.
John Vuko, 510-745-1297
Posted: November 2009